After B.Riley FBR and Cantor Fitzgerald gave Viewray (NASDAQ: VRAY) a Buy rating last month, the company received another Buy, this time from BTIG. Analyst Sean Lavin maintained a Buy rating on Viewray yesterday and set a price target of $13. The company’s shares closed yesterday at $9.09.
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 12.3% and a 60.4% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viewray with a $14.65 average price target, representing a 61.2% upside. In a report issued on October 2, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $13 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.21 and a one-year low of $5.50. Currently, Viewray has an average volume of 1.82M.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ViewRay, Inc. engages in the research, development, and manufacture of magnetic resonance imaging (MRI) system. Its product includes MRIdian, which supports image-guided radiation therapy, stereotactic radiation therapy, and radiosurgery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.
